AR121065A1 - AGENT TO TREAT OR PREVENT DEMENTIA - Google Patents

AGENT TO TREAT OR PREVENT DEMENTIA

Info

Publication number
AR121065A1
AR121065A1 ARP210100097A ARP210100097A AR121065A1 AR 121065 A1 AR121065 A1 AR 121065A1 AR P210100097 A ARP210100097 A AR P210100097A AR P210100097 A ARP210100097 A AR P210100097A AR 121065 A1 AR121065 A1 AR 121065A1
Authority
AR
Argentina
Prior art keywords
dementia
rgma
antibody
treat
agent
Prior art date
Application number
ARP210100097A
Other languages
Spanish (es)
Inventor
Toshihide Yamashita
Takahide Itokazu
Hiroki Uno
Hirokazu Ishida
Original Assignee
Univ Osaka
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Osaka, Mitsubishi Tanabe Pharma Corp filed Critical Univ Osaka
Publication of AR121065A1 publication Critical patent/AR121065A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

Reivindicación 1: Un agente, caracterizado porque es para tratar o prevenir una demencia seleccionada entre demencia diabética y demencia vascular que comprende una sustancia inhibidora de RGMa. Reivindicación 5: El agente preventivo o terapéutico de acuerdo con la reivindicación 4, caracterizado porque el anticuerpo anti-RGMa neutralizante es un anticuerpo humanizado. Reivindicación 6: El agente preventivo o terapéutico de acuerdo con la reivindicación 4 ó 5, caracterizado porque el anticuerpo anti-RGMa neutralizante es un anticuerpo que reconoce una secuencia de aminoácidos seleccionada entre las SEQ ID Nº 16, 36, 37, 38 y 39. Reivindicación 8: Un método para prevenir o tratar una demencia seleccionada entre demencia diabética y demencia vascular, caracterizado porque comprende administrar una dosis eficaz de una sustancia inhibidora de RGMa a un mamífero que necesita del tratamiento.Claim 1: An agent, characterized in that it is for treating or preventing a dementia selected from diabetic dementia and vascular dementia, comprising an RGMa inhibitory substance. Claim 5: The preventive or therapeutic agent according to claim 4, characterized in that the neutralizing anti-RGMa antibody is a humanized antibody. Claim 6: The preventive or therapeutic agent according to claim 4 or 5, characterized in that the neutralizing anti-RGMa antibody is an antibody that recognizes an amino acid sequence selected from SEQ ID Nos. 16, 36, 37, 38 and 39. Claim 8: A method for preventing or treating a dementia selected from diabetic dementia and vascular dementia, characterized in that it comprises administering an effective dose of a RGMa-inhibiting substance to a mammal in need of treatment.

ARP210100097A 2020-01-15 2021-01-15 AGENT TO TREAT OR PREVENT DEMENTIA AR121065A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2020004403 2020-01-15

Publications (1)

Publication Number Publication Date
AR121065A1 true AR121065A1 (en) 2022-04-13

Family

ID=76863789

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210100097A AR121065A1 (en) 2020-01-15 2021-01-15 AGENT TO TREAT OR PREVENT DEMENTIA

Country Status (13)

Country Link
US (1) US20230090965A1 (en)
EP (1) EP4091633A1 (en)
JP (1) JPWO2021145435A1 (en)
KR (1) KR20220113794A (en)
CN (1) CN114945385A (en)
AR (1) AR121065A1 (en)
AU (1) AU2021207010A1 (en)
BR (1) BR112022013944A2 (en)
CA (1) CA3168209A1 (en)
IL (1) IL294769A (en)
MX (1) MX2022008588A (en)
TW (1) TW202140555A (en)
WO (1) WO2021145435A1 (en)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
ATE139258T1 (en) 1990-01-12 1996-06-15 Cell Genesys Inc GENERATION OF XENOGENE ANTIBODIES
EP0546073B1 (en) 1990-08-29 1997-09-10 GenPharm International, Inc. production and use of transgenic non-human animals capable of producing heterologous antibodies
WO1994025585A1 (en) 1993-04-26 1994-11-10 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0652950B1 (en) 1992-07-24 2007-12-19 Amgen Fremont Inc. Generation of xenogeneic antibodies
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
DK2270150T4 (en) 1999-04-09 2019-08-26 Kyowa Hakko Kirin Co Ltd PROCEDURE TO CONTROL THE ACTIVITY OF IMMUNOLOGICAL FUNCTIONAL MOLECULE.
PL218428B1 (en) 2000-10-06 2014-12-31 Kyowa Hakko Kogyo Kk Cells producing antibody compositions
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
EP1688439A4 (en) 2003-10-08 2007-12-19 Kyowa Hakko Kogyo Kk Fused protein composition
EP1733737A4 (en) 2004-03-11 2007-09-05 Bioclues Inc Axon regeneration promoter
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
PL2807192T3 (en) 2012-01-27 2019-02-28 Abbvie Deutschland Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
WO2016175236A1 (en) * 2015-04-28 2016-11-03 田辺三菱製薬株式会社 RGMa BINDING PROTEIN AND USE THEREOF

Also Published As

Publication number Publication date
BR112022013944A2 (en) 2022-09-20
MX2022008588A (en) 2022-08-10
KR20220113794A (en) 2022-08-16
TW202140555A (en) 2021-11-01
WO2021145435A1 (en) 2021-07-22
JPWO2021145435A1 (en) 2021-07-22
EP4091633A1 (en) 2022-11-23
AU2021207010A1 (en) 2022-08-25
CN114945385A (en) 2022-08-26
CA3168209A1 (en) 2021-07-22
IL294769A (en) 2022-09-01
US20230090965A1 (en) 2023-03-23

Similar Documents

Publication Publication Date Title
ECSP045430A (en) COMBINATION THERAPY FOR CANCER TREATMENT
CO2021000326A2 (en) Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for eliminating or reducing immunoglobulins
EA202192122A1 (en) COMPOUNDS WITH FERROPTOSE-INDUCING ACTIVITY AND METHODS FOR THEIR APPLICATION
CL2020002465A1 (en) Fibrotic disease treatment method
BR112022013646A2 (en) METHOD OF TREATMENT OF SPLENOMEGALY
CL2021002176A1 (en) Gremlin-1 inhibitor for the treatment of a bone fracture or defect (divisional of application no. 202002040)
CL2022000214A1 (en) enzyme inhibitors
EA202192528A1 (en) COMBINATION OF PD-1 INHIBITORS AND LAG-3 INHIBITORS TO IMPROVE EFFICIENCY IN CANCER TREATMENT
AR124639A1 (en) COMPOSITION FOR THE TREATMENT OF A VASCULAR DISEASE, THE PREVENTION OF A VASCULAR DISEASE, THE TREATMENT OF HYPERTENSION, OR THE PREVENTION OF HYPERTENSION
CL2022002423A1 (en) Methods to treat Fabry disease
AR121065A1 (en) AGENT TO TREAT OR PREVENT DEMENTIA
CL2022000790A1 (en) Method to treat hiv with cabotegravir and rilpivirine
Avellino et al. Common urologic diseases in older men and their treatment: how they impact fertility
BR112022010750A2 (en) METHOD TO TREAT CANCER USING ARTIFICIAL ADJUVANT CELL (AVC)
AR115722A1 (en) METHOD TO PREVENT OR TREAT PERIPHERAL NEUROPATHIES OR PAIN ASSOCIATED WITH DISEASES THAT HAVE PERIPHERAL NEUROPATHIES OR ASTROCITIC DAMAGE
AR044315A1 (en) AGENT TO PREVENT AND / OR TREAT ACCOMPANYING DISEASES OF TISSUE CHANGES THAT INCLUDE A POLYPEPTIDE
AR127533A1 (en) SARS-CoV-2 INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS
Stoughton Venous ablation therapy: indications and outcomes
MX2022014586A (en) Methods and compositions to treat vascular leak.
BR112022024999A2 (en) TLR7 INHIBITORS IN COMBINATION WITH PREDNISOLONE OR HYDROXYCHLOROQUIN FOR THE TREATMENT OF CUTANEOUS LUPUS ERYTHEMATOSUS
EA202000298A1 (en) ANTICORONAVIRUS AGENT FOR COMBINATION THERAPY OF COVID-19 (SARS-CoV-2) AND METHOD OF TREATMENT
AR120399A1 (en) A METHOD OF TREATMENT OF A DLL3 POSITIVE CANCER
NZ771293A (en) Dosing regimens for treating hypoxia-associated tissue damage
CL2023000702A1 (en) Uses of masp-2 inhibitors to treat sickle cell disease
MX2020007404A (en) Methods and combination therapy to treat cancer.